Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis.
[hodgkin lymphoma, classical]
Due
to
disease
rarity
,
there
is
limited
information
regarding
the
optimal
therapy
and
outcome
for
patients
with
advanced
-
stage
nodular
lymphocyte-predominant
Hodgkin
lymphoma
(
NLPHL
)
.
Forty
-
two
patients
with
NLPHL
by
the
Revised
European-
American
Lymphoma
/
World
Health
Organization
classification
with
advanced
-
stage
disease
were
identified
and
paired
1
:
2
with
a
matched
control
with
classical
Hodgkin
lymphoma
(
CHL
)
matched
by
age
,
gender
,
stage
,
decade
of
diagnosis
,
and
treatment
received
.
The
median
follow-up
was
11
.
3
years
(
range
,
1
.
9
to
35
.
5
years
)
for
NLPHL
patients
and
10
.
7
years
(
range
,
1
.
6
to
26
.
3
years
)
for
CHL
patients
.
The
majority
received
doxorubicin
,
bleomycin
,
vinblastine
,
and
dacarbazine
(
ABVD
)
-
like
chemotherapy
.
Although
the
10
-
year
overall
survival
(
OS
)
(
P
=
.
579
)
and
HL
freedom
from
treatment
failure
(
HL-FFTF
)
were
similar
between
NLPHL
and
CHL
patients
(
75
%
vs
73
%
;
P
=
.
610
)
,
the
time
to
progression
(
TTP
)
,
which
also
includes
the
development
of
secondary
aggressive
lymphoma
,
was
inferior
in
NLPHL
(
10
-
year
,
63
%
vs
73
%
;
P
=
.
040
)
.
Splenic
involvement
was
associated
with
an
inferior
10
-
year
TTP
in
patients
treated
with
ABVD
(
48
%
vs
71
%
;
P
=
.
049
)
and
an
increased
cumulative
incidence
of
secondary
aggressive
lymphoma
(
P
=
.
014
)
providing
a
rationale
for
further
evaluation
of
cyclophosphamide
,
doxorubicin
,
vincristine
,
and
prednisone
(
CHOP
)
with
rituximab
in
NLPHL
.
Diseases
Validation
Diseases presenting
"hodgkin lymphoma"
symptom
esophageal adenocarcinoma
hodgkin lymphoma, classical
monosomy 21
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
This symptom has already been validated